Author

Steven Khoo

Observed names: S Khoo, S. Khoo

Institution: Uniformed Services University of the Health Sciences

Observed institutions: Henry M. Jackson Foundation, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Jackson Foundation

OpenAlex ID: A5078285069

Combined Clinical Trial Results of a HER2/neu(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

2008 · George E. Peoples, Jarrod P. Holmes, et al. · Clinical Cancer Research · 183

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

2010 · Jeremy D. Gates, Guy T. Clifton, et al. · Vaccine · 38

Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients

2006 · E. A. Mittendorf, S. Khoo, et al. · Journal of Clinical Oncology · 5

Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patients

2007 · Carlyle Hamsher, Anna M. Smith, et al. · Cancer Immunology Immunotherapy · 4

HER2/neu Vaccines in Breast Cancer

2006 · Steven Khoo, Sathibalan Ponniah, et al. · Women s Health · 2

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/neu peptide (AE37).

2009 · JD Gates, LC Benavides, et al. · Cancer Research · 1

Immunological monitoring of regulatory T cells by flow cytometry in a novel HLA Class II HER2/neu peptide vaccine clinical trial in breast cancer patients

2006 · Matthew T. Hueman, Steven Khoo, et al. · Journal of the American College of Surgeons · 1

Early results of a phase I clinical trial of an Ii-Key/HER2/neu MHC Class II peptide-based vaccine in breast cancer patients

2006 · Steven Khoo, Catherine Storrer, et al. · Journal of the American College of Surgeons · 1

Developing a predictive model for disease status in breast cancer patients using Th1 and Th2 serum cytokine profiles

2006 · S. Khoo, T. Kao, et al. · Journal of Clinical Oncology · 1

Breast cancer patients have different levels of endogenous CD8 T cells capable of recognizing a HER2/neu peptide (E75) used as a cancer vaccine in clinical trials

2007 · Jarrod P. Holmes, Asna Amin, et al. · Cancer Research

Phase IB trial of the Her2/neu peptide (E75) vaccine for optimal dosing in node-negative breast cancer patients

2006 · E.A. Mittendorf, S. Khoo, et al. · Journal of Surgical Research

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

2006 · S. Khoo, C.E. Storrer, et al. · Journal of Surgical Research

Works count: 12

Citation count: 236

H-index: 4

I10-index: 2